Connect with us
Esteve has expanded internationally by acquiring HRA Pharma Rare Diseases from Perrigo Company plc, adding three drugs for treating Cushing's syndrome and adrenocortical carcinoma. This €275...
Esteve reported a 10% growth in 2023, with net income of €710 million. Revenue grew 2% in Spain, 18% in the EU, and 9% globally, especially...
The company Seagen, which works with improved antibodies that make the drugs more potent, has revenues of $1.5 billion. The biotech company is working with Esteve...